Floatz logo

RETASPIMYCIN

Prostatic Neoplasms

Infinity Pharmaceuticals, Inc.Small moleculePhase 2Dormant
CCC
49/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
34/ 100
Competitive Position
73/ 100

Competitive context

74 Active assets in the Prostatic Neoplasms cohort.

Asset / SponsorPhaseRating
Docetaxel
Merck Sharp & Dohme LLC
Phase 4BBB
Degarelix
Novartis Pharmaceuticals
Phase 4BBB
PREDNISONE TABLETS
Merck Sharp & Dohme LLC
Phase 3BBB
LEUPROLIDE
Dana-Farber Cancer Institute
Phase 4BB
Abiraterone Acetate
Qilu Pharmaceutical Co., Ltd.
Phase 3BB

View all 50 →

Same molecule, other indications

RETASPIMYCIN is also rated in:

prostate carcinomaDormant
CCC
Indicative ·
49 / 100
View asset →
lung cancerDormant
CCC
Indicative ·
48 / 100
View asset →
metastatic melanomaDormant
CC
Indicative ·
46 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →